Amniocentesis: Diagnostic Prenatal Test, Uses, Risks and What It Can and Cannot Tell You

Key takeaways

• Diagnostic, not screening: amniocentesis confirms or does not confirm specific conditions, unlike NIPT or the double/quadruple marker screen, which only estimate risk.
• Targeted, not comprehensive: amniocentesis tests only for the conditions specifically requested; a normal result does not mean a baby free of all abnormalities.
• Timing matters: the test is generally performed from 15 completed weeks; earlier amniocentesis is avoided because of higher complication rates.
• Risk is small but real: pregnancy loss, leakage of fluid, bleeding and infection can occur, so the test is offered only when the information will change care.
• In India, PC-PNDT Act 1994 applies: fetal sex determination or disclosure is a criminal offence, regardless of why the test was done.

At a glance

Also known as

• Amniotic fluid test
• Amniotic fluid sampling
• "Paani ka test" / "pet se paani nikalna", informal terms used by patients in parts of India
• Genetic amniocentesis (when done for chromosomal or genetic diagnosis)
• Therapeutic amniocentesis / amnioreduction (a different procedure done to drain excess fluid, not to diagnose)

What amniocentesis is

Amniocentesis involves passing a fine needle through the abdominal wall and uterine wall into the amniotic sac under continuous ultrasound guidance, and withdrawing a small volume of amniotic fluid. The fluid carries cells shed by the fetus. Those cells are cultured or analysed directly in a genetics laboratory.

The procedure is diagnostic. That means it examines the fetal genetic material itself rather than estimating a probability from maternal blood or ultrasound markers. For the specific conditions tested, amniocentesis gives a far more definitive answer than screening tests, though laboratory limitations still apply.

Why amniocentesis is done

• Chromosomal diagnosis: confirming or excluding trisomy 21 (Down syndrome), trisomy 18 (Edwards syndrome), trisomy 13 (Patau syndrome), sex chromosome aneuploidies and other chromosomal changes.
• Chromosomal microarray: detecting submicroscopic deletions and duplications, particularly useful when ultrasound shows structural anomalies.
• Single-gene disorders: where parents are known carriers, for example thalassaemia, sickle cell disease, spinal muscular atrophy, cystic fibrosis or Duchenne muscular dystrophy, and the familial mutation is already identified.
• Suspected fetal infection: PCR testing of amniotic fluid for cytomegalovirus, toxoplasmosis, rubella or parvovirus B19 when maternal infection is documented.
• Investigating a neural tube defect: amniotic fluid alpha-fetoprotein and acetylcholinesterase can support the diagnosis, though detailed ultrasound is now the mainstay.
• Assessing suspected intra-amniotic inflammation or infection in selected preterm labour or preterm rupture of membranes cases, in specialised units.

Fetal lung maturity testing by amniocentesis, once common, is now rarely performed. Delivery timing decisions are generally made on gestational age and clinical grounds instead.

Who should consider amniocentesis

Amniocentesis is offered, never imposed. It is a choice, and declining it is a legitimate decision. Discussion is usually appropriate when:

• A screening test, NIPT (cell-free DNA), first-trimester combined screening, or the double or quadruple marker test, has returned a high-risk or positive result that needs diagnostic confirmation.
• A detailed ultrasound has shown a structural anomaly or significant soft marker.
• Both parents are carriers of the same recessive condition, such as beta-thalassaemia trait, a common scenario in India, or there is a known familial genetic disorder.
• A previous pregnancy or child was affected by a chromosomal or genetic condition.
• A parent carries a balanced chromosomal rearrangement.
• Maternal infection during pregnancy raises concern about fetal transmission.

Advanced maternal age alone is no longer an automatic indication. Many women in this group now start with NIPT or combined screening and proceed to amniocentesis only if indicated. Results vary depending on individual clinical circumstances, and your fetal medicine specialist will tailor the recommendation.

Amniocentesis may need to be deferred or reconsidered in women with active hepatitis B or C, HIV with a detectable viral load, certain bleeding disorders, or active abdominal skin infection. These are not blanket bars, they require individual assessment and, in some cases, additional precautions.

What amniocentesis cannot detect or exclude

This is the most commonly misunderstood aspect of the test. Amniocentesis answers only the questions it is asked.

• It does not screen for "everything". A standard karyotype reports chromosome number and large structural changes. It does not sequence genes. A normal karyotype says nothing about cystic fibrosis, thalassaemia or thousands of other single-gene conditions unless those specific tests were ordered.
• Chromosomal microarray does not detect balanced translocations or most single-nucleotide mutations, and may report variants of uncertain significance that cannot be clearly interpreted.
• It cannot predict intelligence, behaviour, autism or most learning difficulties.
• It cannot exclude structural birth defects. Heart defects, limb differences and many brain anomalies are diagnosed on ultrasound and fetal echocardiography, not on amniotic fluid.
• It cannot exclude problems that develop later in pregnancy, growth restriction, placental insufficiency, preterm birth or birth injury.
• It cannot predict severity. Many genetic conditions vary widely in how they affect an individual; a diagnosis does not translate into a prognosis.
• A negative result is "not detected", not "excluded". Laboratory failure, culture failure, maternal cell contamination and confined mosaicism can all affect the answer.

If concerns persist despite a normal amniocentesis result, for instance new ultrasound findings or reduced fetal movements, return to your obstetrician rather than relying on the earlier report.

Related but different examinations

Amniocentesis versus chorionic villus sampling (CVS)

CVS samples placental tissue, usually between about 11 and 14 weeks, and so gives an answer earlier. Amniocentesis samples fluid from about 15 weeks. CVS can be complicated by confined placental mosaicism, where the placenta and fetus differ genetically; amniocentesis is less prone to this. Neither test is universally superior, the right choice depends on gestational age at referral, placental position and what is being looked for.

Amniocentesis versus NIPT (cell-free DNA / "NIPS")

NIPT is a maternal blood test. NIPT is a screening test with no procedure-related risk to the pregnancy, but it reports a risk estimate, not a diagnosis. NIPT can give false positives (often from placental mosaicism or a maternal source) and false negatives. A high-risk NIPT result should be confirmed by a diagnostic test such as amniocentesis before any irreversible decision is made.

Amniocentesis versus double marker and quadruple marker tests

These are maternal serum screening tests, combined with ultrasound measurements in the first trimester. They identify pregnancies at higher risk and are far less specific than amniocentesis. They cannot diagnose anything.

Amniocentesis versus fetal blood sampling (cordocentesis)

Cordocentesis samples fetal blood from the umbilical cord. It is used for rapid karyotyping, fetal anaemia assessment and intrauterine transfusion. Cordocentesis carries a higher procedure-related risk than amniocentesis and is reserved for specific indications.

Diagnostic amniocentesis versus amnioreduction

Amnioreduction drains a large volume of fluid to treat symptomatic polyhydramnios or twin-to-twin transfusion syndrome. Although the needle technique is similar, the purpose, volume removed and risk profile are different.

Amniocentesis versus anomaly scan

The 18-22 week anomaly scan assesses fetal structure. Amniocentesis assesses fetal genetics. They answer different questions and are frequently used together.

How to prepare

Preparation instructions are operational and vary between hospitals and fetal medicine units. Your unit's written instructions take precedence over anything you read here.

• Counselling first: most units require pre-test genetic counselling and written informed consent, explaining what will and will not be tested.
• Blood group and antibody status: if you are Rh-negative, anti-D immunoglobulin is usually given after the procedure. Tell the team if you are unsure of your blood group.
• Infection screening: hepatitis B, hepatitis C and HIV status are usually checked beforehand, as they influence technique and precautions.
• Bladder: some units prefer an empty bladder, others a partially full one, depending on gestation and uterine position. Follow your unit's instruction rather than a general rule.
• Eating and drinking: fasting is generally not required. Do not fast unless your unit specifically asks, and if you have diabetes on glucose-lowering treatment, tell the team before any fasting instruction is applied.
• Medicines: do not stop aspirin, low-molecular-weight heparin or any other prescribed blood thinner on your own. Tell the doctor who prescribed it and let the fetal medicine team decide together with the prescriber.
• Bring someone with you if you can. Arranging transport home is sensible, as rest is advised afterwards.

If you have heart failure, advanced kidney disease or a fluid restriction

Do not follow generic "drink plenty of water" advice. Tell the unit about your condition so hydration instructions can be adjusted safely with your treating physician.

If you have diabetes on insulin or tablets

Clarify meal and medication timing in advance. Unplanned skipped meals can cause hypoglycaemia.

If you have a bleeding disorder or take anticoagulants

The procedure may still be possible, but timing around your medication needs planning with your haematologist or prescriber.

Multiple pregnancy

Twin and triplet pregnancies require sampling of each sac, with dye or careful mapping to avoid duplicate sampling. The procedure is technically more demanding and the risk profile differs from a singleton pregnancy.

What happens during amniocentesis

• Ultrasound survey: the doctor checks fetal heartbeat, gestational age, placental position and identifies a pocket of fluid away from the fetus and cord.
• Skin cleaning: the abdomen is cleaned with antiseptic and draped. Local anaesthetic may or may not be used, practice varies and evidence for benefit is limited.
• Needle passage: a fine spinal-type needle is advanced under real-time ultrasound guidance into the fluid pocket.
• Sampling: a small volume of amniotic fluid is aspirated. The first small amount may be discarded to reduce maternal cell contamination.
• Needle removal and check: the needle is withdrawn, the fetal heartbeat is confirmed and the puncture site is dressed.
• Observation: most units observe you for a short period before discharge.

How long it takes: the appointment usually runs 30-60 minutes including counselling, scanning and observation. The needle itself is typically in place for well under two minutes. Occasionally a second attempt is needed if fluid is not obtained; most units will not attempt more than twice on the same day.

Afterwards

Mild cramping and a dragging ache for a day or so are common. Most units advise avoiding heavy lifting, strenuous activity and intercourse for a short period, typically a day or two, but follow your unit's advice. Normal daily activity is usually resumed the next day.

Understanding your report

Amniocentesis reports are tailored to the tests requested, so two reports may look very different. Common components include:

• Rapid aneuploidy test (QF-PCR or FISH): reports on chromosomes 13, 18, 21, X and Y only. A normal rapid result does not comment on any other chromosome.
• Karyotype: a full chromosome count and structural assessment, reported in standard cytogenetic notation. Requires cell culture, so takes longer.
• Chromosomal microarray: detects gains and losses of chromosomal material too small for karyotype. May report variants of uncertain significance.
• Targeted gene test: reports only on the specific familial mutation tested.
• Infection PCR: reports whether the organism's genetic material was detected in the fluid. Detection does not always predict how severely the fetus is affected.

No amniocentesis report should be interpreted on its own. The fetal medicine specialist or genetic counsellor who requested the test will read it alongside the ultrasound findings, your family history and carrier status. Do not interpret a report from an internet search.

Because of the PC-PNDT Act 1994, fetal sex, even when incidentally revealed by chromosome analysis, is not disclosed to the family in India, and laboratories and clinicians are legally bound by this.

When results can be misleading

Results that can falsely suggest an abnormality

• Mosaicism in culture: a chromosomal change may arise in the cultured cells rather than in the fetus (pseudomosaicism), suggesting a problem that is not present. Confirmatory testing is usually needed.
• Variants of uncertain significance on microarray: a genetic change is found, but its meaning is unknown. This causes considerable anxiety without giving a diagnosis. Parental testing may help clarify it.
• Raised amniotic fluid alpha-fetoprotein from a bloody tap: fetal blood contaminating the sample can elevate AFP and mimic a neural tube defect.

Results that can falsely reassure

• Maternal cell contamination: maternal cells in the sample can mask a fetal abnormality, particularly in a male fetus, producing a spuriously normal female result.
• Narrow test scope: a normal rapid QF-PCR is limited to five chromosomes. A normal karyotype misses microdeletions. A normal microarray misses single-gene disorders. Each "normal" applies only to what was examined.
• Low-level fetal mosaicism may not be picked up in the cells sampled.
• Early infection sampling: if amniocentesis for suspected fetal infection is done too soon after maternal infection, the organism may not yet be detectable in the fluid, and repeat testing may be advised.

Technical factors

• Culture failure: occasionally cells fail to grow and a repeat sample is needed.
• Higher maternal BMI, fibroids or an anterior placenta can make sampling technically harder and increase the chance of a failed or bloody tap.
• Sampling before 15 weeks yields fewer cells and is associated with higher complication rates, which is why it is avoided.

Risks and safety

Amniocentesis is an invasive procedure. It is not risk-free, and no honest account can describe it as completely safe. Risks differ by procedure type and clinical setting.

Diagnostic amniocentesis after 15 weeks (singleton pregnancy)

• Pregnancy loss: a small excess risk above the background miscarriage rate. Contemporary estimates from experienced centres are lower than older figures, but no single number applies to every woman or every unit. Ask your fetal medicine specialist for their unit's counselling figure.
• Leakage of amniotic fluid: usually small and often self-sealing, but occasionally persistent.
• Vaginal bleeding or spotting.
• Intrauterine infection: uncommon but potentially serious.
• Needle injury to the fetus: rare with continuous ultrasound guidance.
• Rhesus sensitisation in Rh-negative women, which is why anti-D is given.
• Cramping and discomfort for a day or two, common and usually self-limiting.

Early amniocentesis (before 15 weeks)

Associated with higher rates of pregnancy loss, fluid leakage and talipes. It is no longer recommended.

Multiple pregnancy

Risk of loss is higher than in singleton pregnancies because more than one sac is entered. Counselling should be specific to twins or higher-order multiples, not borrowed from singleton figures.

Amnioreduction

Because a much larger fluid volume is removed, the risks of membrane rupture, placental abruption and preterm labour differ from diagnostic amniocentesis. Safety statements for one do not transfer to the other.

Results and complication rates vary depending on individual clinical circumstances, operator experience and gestational age.

Special situations

Rh-negative mothers

Anti-D immunoglobulin is normally offered after amniocentesis to reduce the risk of rhesus sensitisation. Confirm with the team that this has been arranged before you leave.

Women with hepatitis B, hepatitis C or HIV

Amniocentesis is not automatically ruled out, but the risk of vertical transmission must be weighed. In HIV, suppression of viral load with antiretroviral therapy before the procedure is usually preferred. Decisions are individualised with your infectious disease and obstetric teams.

Older mothers

Age raises the background chance of chromosomal conditions but does not by itself make amniocentesis necessary. Many women start with NIPT and proceed only if a result warrants it.

Women with fibroids or previous abdominal surgery

Fibroids and adhesions can limit needle access. The operator may need a different entry site, and occasionally the procedure is rescheduled.

Women with anxiety or a history of pregnancy loss

The wait for results is difficult. Ask your unit about rapid testing options, counselling and clear timelines before the procedure.

Consanguineous couples and known carrier couples

Where both parents carry the same recessive condition, the familial mutation should ideally be identified before pregnancy or early in pregnancy, so the amniotic fluid can be tested directly for it.

Amniocentesis in the Indian context

PC-PNDT Act 1994. The Pre-Conception and Pre-Natal Diagnostic Techniques (Prohibition of Sex Selection) Act governs all prenatal diagnostic procedures in India. Amniocentesis may only be performed at a registered facility, by registered practitioners, for permitted medical indications, with prescribed consent and record-keeping. Communicating the sex of the fetus to anyone, in any form, is a criminal offence. Legitimate genetic testing is entirely lawful under this framework; the prohibition is on sex disclosure and sex selection.

Haemoglobinopathies. Beta-thalassaemia trait and sickle cell trait are common in several Indian populations. Where both partners are carriers, prenatal diagnosis by amniocentesis with targeted mutation analysis is a well-established indication. Ideally both partners' mutations are characterised beforehand so the fetal sample can be tested accurately.

Access and counselling. Fetal medicine units and clinical genetics services are concentrated in larger cities, and genetic counselling capacity is limited in many regions. Ask specifically whether a genetic counsellor is available before and after the test, pre-test counselling materially affects how useful the result will be.

Terminology. Patients and referring doctors may use "double marker", "quadruple marker", "NIPT", "NIPS" and "anomaly scan" interchangeably in conversation. These are distinct tests; clarify which one you have had before assuming amniocentesis is needed.

Legal timeframes. Decisions following an abnormal diagnosis are governed by the Medical Termination of Pregnancy (Amendment) Act 2021, including provisions for substantial fetal abnormality assessed by a Medical Board. Discuss timelines early, because delays in testing can narrow available options.

Cost and insurance in India

The cost of amniocentesis in India varies widely, and the procedure fee is usually only a fraction of the total. Costs are best confirmed directly with the facility before booking.

• Procedure fee: ultrasound guidance, operator time, consumables and day-care observation.
• Laboratory tests ordered: the dominant cost driver. Rapid QF-PCR, full karyotype, chromosomal microarray, exome sequencing and targeted mutation analysis differ substantially in price, and microarray and sequencing are considerably more expensive than karyotype.
• Genetic counselling sessions, which may be billed separately.
• Anti-D immunoglobulin for Rh-negative women.
• Repeat testing if culture fails or confirmation is required.
• City and facility type: metro tertiary centres and referral genetics laboratories generally charge more than smaller centres.
• Sample transport if the fluid is sent to an external reference laboratory.

Insurance: coverage for prenatal diagnostic testing varies considerably between insurers and policies, and outpatient or day-care investigations are often excluded even when maternity benefits exist. Waiting periods for maternity cover commonly apply. Check the specific policy wording and obtain written pre-authorisation where possible rather than assuming cover.

Myths and facts

Frequently asked questions

How long does the amniocentesis procedure take?

The hospital visit usually takes 30-60 minutes including counselling, scanning, the procedure and a short observation period. The needle itself is generally in the uterus for under two minutes. Plan for a longer visit if consent, blood tests or anti-D administration are being arranged on the same day.

Does amniocentesis hurt?

Most women describe a sharp sting as the needle passes the skin, then a dull pressure or period-like cramp. Pain is usually brief and tolerable without anaesthesia, though experience varies. Tell the operator if you are uncomfortable; some units offer local anaesthetic, and practice differs between centres.

How soon will I get results?

Rapid tests such as QF-PCR for common trisomies usually report within a few working days. Full karyotype requires cell culture and takes longer, and chromosomal microarray timelines differ again. Ask your unit for its own expected reporting window before the procedure so the wait is predictable.

Should I have NIPT or amniocentesis?

They serve different purposes. NIPT is a maternal blood screening test with no procedure risk but only estimates probability. Amniocentesis is diagnostic and carries a small procedure risk. Many women begin with NIPT and proceed to amniocentesis only if screening or ultrasound raises concern.

Can amniocentesis be done before 15 weeks?

Amniocentesis before 15 completed weeks is associated with higher rates of pregnancy loss, amniotic fluid leakage and talipes, and is no longer recommended. If earlier diagnosis is needed, chorionic villus sampling from about 11 weeks is usually the preferred alternative.

Will the amniotic fluid removed harm my baby?

Only a small volume is removed for diagnostic amniocentesis, and the body replaces it. This differs from amnioreduction, where a much larger volume is drained therapeutically and the risk profile is different. Persistent leakage afterwards is uncommon but should be reported the same day.

What happens if the result is abnormal?

You will be offered a detailed discussion with a fetal medicine specialist and genetic counsellor covering what the finding means, how confident the diagnosis is, what further tests may help, and the options available. Time is usually given for reflection and a second opinion where you want one.

Can amniocentesis be repeated?

Yes, occasionally. Repeat sampling may be needed if cell culture fails, if maternal cell contamination is suspected, or if a mosaic result needs confirmation. A repeat procedure carries its own risks, which your fetal medicine specialist will discuss before proceeding.

Is amniocentesis compulsory if my screening test was high risk?

No. Amniocentesis is always a choice. Some women decline diagnostic testing because the result would not change their care. Others want certainty for planning delivery and neonatal care. Both are valid decisions, and declining does not affect the rest of your antenatal care.

Sources

• Pre-Conception and Pre-Natal Diagnostic Techniques (Prohibition of Sex Selection) Act, 1994, Government of India, and subsequent rules and amendments.
• Medical Termination of Pregnancy (Amendment) Act, 2021, Government of India.
• Royal College of Obstetricians and Gynaecologists, Green-top Guideline on Amniocentesis and Chorionic Villus Sampling.
• American College of Obstetricians and Gynecologists, Practice Bulletins on Prenatal Diagnostic Testing for Genetic Disorders and Screening for Fetal Chromosomal Abnormalities.
• International Society of Ultrasound in Obstetrics and Gynecology (ISUOG), Practice Guidelines on invasive prenatal procedures.
• Indian Council of Medical Research guidance on prenatal diagnosis of haemoglobinopathies.